Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses

Trial Profile

A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Girentuximab Zr-89 (Primary)
  • Indications Renal cell carcinoma
  • Focus Diagnostic use; Registrational
  • Acronyms ZIRCON
  • Sponsors Telix Pharmaceuticals
  • Most Recent Events

    • 10 Oct 2019 According to a Heidelberg Pharma media release, the first patient in Australia was recruited in August 2019.
    • 13 Jun 2019 According to a Telix Pharmaceuticals media release, Eczacibasi-Monrol and Telix Pharmaceuticals have signed a manufacturing and distribution agreement in which there will be an addition of four Turkish clinicl sites for this trial.
    • 08 Apr 2019 Planned initiation date(estimated date for recruitment of the first subject) changed from 1 Mar 2019 to 15 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top